News Releases

A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penn’s Abramson Cancer Center reported today in the New England Journal of Medicine.

After a rapid mobilization of its telemedicine infrastructure to ensure continuity of care for patients of all kinds during the hectic days of March 2020, Penn Medicine marked telemedicine visit number one million this week.

The mutation of a gene that has been associated with neurodevelopmental disorders like autism spectrum disorder led to marked sleep disturbances in fruit flies, according to a new study from scientists in the Perelman School of Medicine at the University of Pennsylvania.

Even as COVID-19 vaccine distribution ramps up in Philadelphia, the virus remains prevalent, and shoring up testing capabilities is a key way to protect local residents. Penn Medicine has tapped into a workforce in its own backyard to expand testing efforts in the area: Through the University City District’s West Philadelphia Skills Initiative (WPSI), the health system has hired 50 new laboratory assistants, who will play a pivotal role in collecting and processing large quantities of testing samples.

International cancer cell therapy pioneer Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania and director of the Center for Cellular Immunotherapies at Penn’s Abramson Cancer Center, has been named a 2021 Dan David Prize Laureate.

“Understanding the psychology of the ‘anomalous-is-bad’ stereotype can help, for example, in the design of interventions to educate the public about the social burdens shouldered by people who look different,” said lead author Clifford Workman, PhD, a postdoctoral researcher in the Penn Center for Neuroaesthetics.